Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for Refractory Crohn's Disease
NCT05262829Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Feb 2022
- Primary completion
- Aug 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of human umbilical cord mesenchymal stem cells in Crohn's disease, sponsored by Shanghai East Hospital. Primary endpoints: Crohn's Disease Activity Index at 24 weeks and Simplified Endoscopic Score for Crohn's Disease at 24 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05262829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262829.